News Releases

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON , June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments

BOSTON , May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024 . Mr.

- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024- - Completed up to $149.4 million private placement with leading healthcare investors in early 2Q

- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital , Special Situations Funds and Soleus Capital ; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on

BOSTON , March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in the following three investor conferences during the month of April:

Funding from new investors, including RA Capital Management , Armistice Capital , Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied to exercise of warrants Pro forma cash and cash equivalents from upfront proceeds expected to

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) -   Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes (CDR-SB) - Scientific collaborators from University College London (UCL) present

BOSTON , Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will present at the BIO CEO and Investor Conference on February 26, 2024 , being held

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies - -RewinD-LB trial remains on track to complete

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON , Feb.